<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Jun Axup on Medium]]></title>
        <description><![CDATA[Stories by Jun Axup on Medium]]></description>
        <link>https://medium.com/@junaxup?source=rss-f6e138c7590b------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/2*IaVOeHSINqS42YahpecDkA.png</url>
            <title>Stories by Jun Axup on Medium</title>
            <link>https://medium.com/@junaxup?source=rss-f6e138c7590b------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Wed, 18 Nov 2026 04:53:44 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@junaxup/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Egg Freezing Guide]]></title>
            <link>https://junaxup.medium.com/egg-freezing-guide-a4c5d6adea6b?source=rss-f6e138c7590b------2</link>
            <guid isPermaLink="false">https://medium.com/p/a4c5d6adea6b</guid>
            <category><![CDATA[ivf]]></category>
            <category><![CDATA[in-vitro-fertilization]]></category>
            <category><![CDATA[egg-freezing]]></category>
            <category><![CDATA[fertility]]></category>
            <category><![CDATA[family-planning]]></category>
            <dc:creator><![CDATA[Jun Axup]]></dc:creator>
            <pubDate>Sat, 18 Sep 2021 20:49:27 GMT</pubDate>
            <atom:updated>2021-09-22T17:29:31.855Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*q3OEwqejKWfO5aylDE4C5g.png" /><figcaption>Credit: Google Images [<a href="https://images.app.goo.gl/wDfDtmKGjqQXmNw57">1</a>, <a href="https://images.app.goo.gl/ogrnseJnxECzxGde6">2</a>]</figcaption></figure><p>I finally froze my eggs after years of debating and seeing other friends go through the process. All in all, it was a rather easy and successful process. Here, I share my experiences and all the details I learned to help others make this important decision for themselves. My experiences are specific to the <a href="https://rmanetwork.com/our-locations/rma-northern-california/san-francisco-ca/">RMA clinic</a> in San Francisco (which I highly recommend) and limited to the technology and financing instruments available in 2021.</p><h4>Table of Contents:</h4><blockquote><em>1. </em><a href="#ec4c"><em>Whether/when to freeze eggs?</em></a><em><br>2. </em><a href="#2f95"><em>Choosing a Provider</em></a><em><br>3. </em><a href="#5dfa"><em>Cost Breakdown</em></a><em><br>4. </em><a href="#bb5e"><em>The Appointments</em></a><em><br>5. </em><a href="#2502"><em>The Drugs</em></a><em><br>6. </em><a href="#15df"><em>The Surgery</em></a><em><br>7. </em><a href="#c9ed"><em>FAQ: Egg freezing with IUD?</em></a><em><br>8. </em><a href="#4836"><em>FAQ: What are the biggest risks and how to prevent them?</em></a><em><br>9. </em><a href="#c0bf"><em>FAQ: Lupron &amp; Ovarian Hyperstimulation Syndrome</em></a><em><br>10. </em><a href="#7ae2"><em>FAQ: Does egg extraction reduce the number of eggs left in me?</em></a><em><br>11. </em><a href="#62bd"><em>Miscellaneous Tips</em></a></blockquote><h3><strong>1. Whether/when to freeze eggs?</strong></h3><p>You’ve probably heard the numbers. At age 35, women start declining in reproductive capacity. For those of us who are not ready to have kids by then, egg freezing is increasingly becoming a viable option.</p><p>First of all, egg freezing is a deeply personal decision. It should not be influenced by what your partner wants or whether your friends are doing it.</p><p>I had debated for years whether to undergo the procedure and held back because it’s a large chunk of money ($12–15K), comes with potential side effects (see <a href="#4836">FAQ</a>), and my fertility number (AMH) was still pretty high that I thought I probably could just have a kid naturally.</p><p>This year, I finally decided to do it because of a few unusual reasons:</p><ol><li>Ideally, I would like to have my first kid naturally in my late 30’s. However, freezing my eggs now would be helpful for a future second kid who I may want in my 40s.</li><li>IVF and embryo selection technology is getting better and better every year. However, what does not get better are my eggs themselves. In order to take advantage of new advances, it’s better to freeze my eggs while I’m younger for both the egg’s health and that the procedure would be less taxing on my body.</li><li>Stem cell technology might one day be useful for my own health in the future. That’s why I saved my bone marrow with <a href="https://foreverlabs.com/">Forever Labs</a>. Might as well save my eggs too.</li></ol><h4><strong><em>How many eggs to save?</em></strong></h4><p>The numbers hugely depend on your goals and number of follicles you have. We reduce in follicles as we age (average 15 follicles before 35 years old). Perhaps 50–70% of those follicles will produce mature eggs, then ~70% of them will fertilize, ~45–50% grow to a blastocyst, some percent will be chromosomally normal. You are now looking at only 2–3 embryos for one baby (<a href="https://www.mdcalc.com/bwh-egg-freezing-counseling-tool-efct">see estimate tool</a>).</p><p>I decided to aim for freezing 20 eggs to give me a good chance of having two babies from them. I was preparing to do two cycles if I needed to.</p><h3><strong>2. Choosing a Provider</strong></h3><p>The IVF market is booming and every few months there’s a new private provider for IVF and egg freezing. Many of my friends who did egg freezing years ago went to <a href="https://crh.ucsf.edu/">UCSF</a>, but there are all kinds of smaller fertility clinics. I was recommended places like <a href="https://springfertility.com/">Spring Fertility</a> and <a href="https://www.laurelfertility.com/">Laurel Fertility Care</a>. I ended up going with <a href="https://rmanetwork.com/our-locations/rma-northern-california/san-francisco-ca/">RMA</a> due to two factors: their amazing scores on <a href="http://fertilityiq.com/">FertilityIQ</a> and that I was able to book an appointment the following week instead of waiting 3 months (as UCSF and Spring Fertility tried to offer me).</p><p>Some other important factors when making a decision:</p><ol><li><strong>Location</strong>: you will need to visit the clinic (usually early in the morning) 6–8 times during the procedures. You might also experience cramps in which it may be difficult for you to drive. Finding a clinic close to home that you can take a Lyft to is very convenient.</li><li><strong>Staff consistency and communication</strong>: while you will be assigned to a primary doctor, the intermediate visits to monitor your egg development are often done by different doctors or nurses. Working with a smaller clinic might have more consistency and communication between staff. You can get a peek of how different clinics work via <a href="http://fertilityiq.com/">FertilityIQ</a>.</li><li><strong>Trust</strong>: As humans we are swayed by our emotions. If a doctor or clinic doesn’t feel quite right, it may influence your trust in the procedure. I found <a href="http://fertilityiq.com/">FertilityIQ</a> reviews very helpful to gain more trust in the doctors I was working with. It calmed my anxiety and made me feel like I was taken care of.</li></ol><h3><strong>3. Cost Breakdown</strong></h3><p>Clinics can charge anywhere between $5,000–10,000 for the procedure, then $2,000–5,000 for drugs (dosing and length of injections varies depending on how you respond), and $600/year for storage. Most clinics will have a discount (~10%) to do subsequent procedures, but the drugs will cost the same.</p><p>Here are my exact costs (yours may vary):</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/725/1*vFcT1aA2WhlBO3Zg3lFh4g.png" /><figcaption>¹ RMA uses a third party for anesthesia, so the cost is billed separately. Most other places will include anesthesia into the procedure price. ² On the website, it says lab consultation is $400. I think it was an estimate as mine came out to be lower for the particular tests they ordered.</figcaption></figure><h4><strong><em>Insurance</em></strong></h4><p>As egg freezing is considered an elective procedure, I had to pay all of this out of pocket. There are insurances that cover egg freezing, such as <a href="https://progyny.com/">Progeny</a>, but often they must be provided as a benefit from your company. If you undergo the procedure as a part of IVF, most insurance will have some form of coverage. RMA worked with my insurance and was able to bill some parts of the labs and anesthesia through my insurance provider. This at least counted towards my deductible for the year.</p><p>There are options to get your egg freezing paid for by donating half the eggs to a family in need. Programs like <a href="https://freezeandshare.com/">Freeze and Share</a> and <a href="https://www.myeggbank.com/">My Egg Bank</a> can pass on the egg extraction costs to a beneficiary. This was an attractive and altruistic option I considered, however, because I wanted to save 20 eggs, it was unlikely I could donate and have enough from one cycle. I would end up paying for a cycle myself anyways.</p><h4><strong><em>Storage</em></strong></h4><p>At RMA, retrieved eggs are stored in liquid nitrogen tanks that are constantly monitored and refilled. Some people decide to split up the eggs into two different facilities to mitigate any accidents (which is unlikely but can happen). RMA recommended <a href="https://www.reprotech.com/">Reprotech</a> in Nevada. Personally, I decided not to do a backup because freezing eggs was already my backup plan, and I wouldn’t be heartbroken on the very slim chance that the backup failed. For those who see their eggs as a lifeline, it might be a good idea to split the storage.</p><p>Storage costs $600 per year with the first year free. As part of the paperwork, you can decide on what happens to the eggs in case you default on the bills. The options are to throw the eggs away or to donate it to research. You can also assign custody of the eggs to a partner or family member in case of your passing.</p><p>Often institutes don’t keep your credit card on file, so definitely mark it in your calendar to pay your bills proactively to prevent your eggs being tossed.</p><h3><strong>4. The Appointments</strong></h3><p>Part of the reason I chose RMA as my provider was because they were able to schedule a consultation appointment a week from when I first called them. Other providers I had inquired from only had appointments in 3 months.</p><h4><strong><em>Consultation Appointment</em></strong></h4><p>My initial consultation was about 1.5 hours where the nurse practitioner patiently went over every aspect of the procedure and answered all my questions. She asked for my medical history and family’s medical history.</p><p>They required a host of blood tests and an ultrasound exam to count the number of follicle and see their state. For banking, they need to verify that I had no STDs. You can submit any tests that were done within the last year, otherwise they would run a test during the consultation appointment.</p><p>The tests were:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/860/1*Kx377IPfS-RSeag1qluslg.png" /></figure><p>The consultation appointment was billed separately and cost $269.43 for me. I had some of the tests done recently at my yearly physical and didn’t have to do them again.</p><h4><strong><em>When to Start</em></strong></h4><p>The doctor will instruct when in your cycle to start. Usually it’s after the 3rd day of your period. For some people, birth control pills are needed to sync your cycle more precisely. I have a hormonal IUD and it actually made it easier. As long as the follicles were in a resting state, I was able to start immediately. (See <a href="#c9ed">FAQ: Egg freezing with IUD?</a>).</p><p>Once you start injections, you can not drink more than one cup of caffeine per day and absolutely no alcohol. They recommend avoiding exposure to chemicals, X-rays, or other medication. To prevent the risk of ovarian torsion, do not engage in intense exercise or intercourse starting on day 5 of injection. Ovarian torsion is when the ovary twists around the surrounding supportive tissue and cuts off blood flow. If this happens, you will feel extremely sharp pain in the abdomen (the crying on the floor type) and will need to immediately go to the Emergency Room for surgery. This is very rare (&lt;0.1% chance).</p><h4>Monitoring Appointments</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/488/1*1WWv27KUrF2B1fa-Z128Wg.png" /><figcaption>Ultrasound monitoring of my eggs. Retrieval happens when the majority of eggs reach 15–22 mm in size.</figcaption></figure><p>Every couple of days, you will go in for ultrasound and blood tests (for estrogen and progesterone) to monitor the progression of the follicles developing. The first week will be two shots per night (FSH and Menopur). Then, a third shot will be introduced (Cetrotide) until the follicles reach 15–22 mm in diameter, as monitored by ultrasound. When it is time, the doctor will instruct you to administer the trigger shot (mine was Lupron) exactly 36 hr before the surgery and then another dose 24 hrs before. More about these drugs in the next section (<a href="#2502">The Drugs</a>).</p><p>My schedule looked like this (yours may vary):</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/931/1*Ihy68mCGrrT8T7AiW1igrA.png" /></figure><h3><strong>5. The Drugs</strong></h3><p>So, what are the shots and what do they do?</p><p>The first week comprises of two drugs to mimic your natural Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). These hormones normally are made in your body to start the follicle development process. Menopur is a combination of FSH and LH. FSH is then supplemented with another drug that comes in two brands (Gonal F or Follistim). Depending on your bloodwork, you will be assigned specific doses to follow and these doses may be adjusted by your doctor. All injections need to be prepared (some already liquid and others need to be dissolved) by their respective procedures, cleared of air bubbles, and injected 90 degrees into the abdomen.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/300/0*yMJkZ2cP6tWgsb2N" /><figcaption>Credit: <a href="https://images.app.goo.gl/3bKbiJ9CKwmhxriEA">Google Images</a></figcaption></figure><p><strong>Gonal F</strong> comes as a neat pen where you can dial in the dose. Each pen is about 350 units, so for my dose of 150 units, I would dial in 150 after priming the needle. I would recap the pen and use it the next night. The needle on this was very thin and didn’t hurt at all going in. I would push the button slowly and watch the counter move. I had no problems with this injection.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/332/1*g4TfSedXk5kVMYzHUE84VQ.png" /><figcaption>Credit: <a href="https://images.app.goo.gl/GzPMGSq4W6jWUGMh6">Google Images</a></figcaption></figure><p><strong>Menopur</strong> comes in powdered vials. Since I needed two vials, I would draw up 1 mL of sterile saline to dissolve one vial, and then transfer all the liquid to dissolve the second vial. The preparation is rather easy once you get the hang of it. I did experience slight discomfort when injecting Menopur. As the liquid is being injected, there is a slight sense of burning. However, it went away as soon as I was done injecting.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/379/1*duMNQnMUz_mQkNkNMoum0g.png" /><figcaption>Credit: <a href="https://images.app.goo.gl/Fxbmjpi8XE5Xmvn89">Google Images</a></figcaption></figure><p>After the first week, I was instructed by my doctor to incorporate a third drug while continuing the first two. This was <strong>Cetrotide</strong> (or Ganirelix, another brand), which is used to prevent ovulation. As your body is getting all the FSH and LH hormones, your estrogen will start to increase to a point where normally ovulation will happen. We want to prevent this, so Cetrotide is used. It keeps all the eggs in place until they get to the right size to be harvested.</p><p>I had the most symptoms with this injection. The injection itself went in easy with no pain, but a minute later I would develop a histamine response where my skin would get itchy and red. This lasted for a few hours. The doctor did assure me this is a common side effect for the drug. Additionally, I found the preparation of this to be more challenging than the others. It came as a pre-filled saline syringe that you would use to dissolve the vial of powder. This drug took longer to dissolve than Menopur. The syringe itself also was a bit finicky to work with.</p><p>Finally when the eggs are at the desired size, your doctor will give directions to inject the trigger shot precisely 36 hrs before your surgery appointment. This shot is <strong>human chorionic gonadotropin (hCG) or Lupron</strong> (an agonist of hCG). This mimics a high dose of Luteinizing Hormone, which gets the eggs to mature, but does not cause ovulation. Traditionally, the trigger shot can be Ovidrel, Novarel, or Pregnyl.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/250/0*pO4FFcbHbRNvgCrC.jpg" /><figcaption>Credit: <a href="https://images.app.goo.gl/v7sfkDGNpH54TgJQ7">Google Images</a></figcaption></figure><p>My doctor prescribed me Lupron. Lupron is a newer drug used in IVF especially for those at risk of Ovarian Hyperstimulation Syndrome (OHSS) and requires a second dose 24 hrs before surgery. OHSS is higher risk for those with high AMH and can cause fluid to leak into the abdomen after egg retrieval, creating a lot of pressure. In severe cases, the fluid will need to be surgically extracted. If this happens, it will be in the couple of days following surgery. OHSS does not happen with Lupron.</p><p>Lupron is provided in liquid form and simply drawn out with the provided syringe to the dose instructed by your doctor. I did not have any issues with administration.</p><p>Last note is that it was common for me to have a drop of blood after injection. I would press a tissue paper on my injection site and it would stop bleeding rapidly. I also ended up bruising myself a few times, which is all normal.</p><h3><strong>6. The Surgery</strong></h3><p>Throughout the process, I had been limiting my activity, partly to avoid catching COVID and to avoid ovarian torsion. The last two days before my surgery, I was feeling some pressure from my ovaries and it was cramping when I stood or sat up. Luckily it was the weekend, so I gave myself the excuse to lay down and watch movies.</p><p>On the surgery day, I was to arrive an hour early and have someone pick me up because I would be undergoing general anesthesia. It was also advised that I should take the rest of the day off from work and not make any important decisions that day.</p><p>All of my checkup appointments were done in typical primary care type rooms. The surgery was in a completely separate wing that looked more like the ER. I changed into a gown and laid on a hospital bed while the doctor and nurses checked in with me and installed an IV lead into my arm.</p><p>When it was my turn, I was led into the operating room, which was rather intimidating as a team of nurses started to strap me into the table. The anesthetist gave me an oxygen tube in my nose and started my IV. I very quickly fell asleep.</p><p>And that was it. I woke back up in the hospital bed. I was probably out for 30 minutes. It took me another 20 min to feel well enough to get up.</p><p>I experienced more cramping than before the surgery for the next few days. Sometimes the pain was intense, but often did not last long and may be due to my badder pushing on my ovaries. Definitely take the time to rest and drink electrolytes. It is still recommended not to do strenuous activities or exercise until your next period to prevent ovarian torsion. Spotting is also normal.</p><p>Not all your eggs will be at the right size for harvesting and not all of them will be mature. On the afternoon of the surgery, the doctor told me the final number of mature eggs that were frozen. And we rejoiced!</p><h3><strong>7. FAQ: Egg freezing with IUD?</strong></h3><p>Yes! The whole procedure can be done without removing your IUD. It’s actually easier to start with a hormonal IUD because you don’t have to sync up your cycle. The doctors can tell by blood tests and ultrasound when it’s good to start. Because the doctor uses a syringe to pierce into the ovaries from the side wall of the vagina to extract the eggs, there is no disruption to the uterus and any contents within.</p><h3><strong>8. FAQ: What are the biggest risks and how to prevent them?</strong></h3><p>There are 3 major risks (all of which happen very rarely):</p><ol><li><strong>Ovarian torsion</strong> — this is when the ovary twists on its surrounding tissue and cuts off blood flow. If this happens, you will experience extremely sharp pain and will need to rush to the ER immediately for surgery. Ovarian torsion can be prevented by limiting exercise, including intercourse, starting on the 5th day of injections and through to 2 weeks after the surgery.</li><li><strong>Ovarian Hyperstimulation Syndrome </strong>— this can happen after the egg extraction when fluid fills into the empty follicles and leaks into the abdomen. This often is experienced as cramping and bloating. In extreme cases, surgery will be needed to drain the follicles of fluid. If you are at high risk of OHSS, your doctor may prescribe Lupron as the trigger shot, which does not have the side effect of OHSS.</li><li><strong>Anesthesia</strong> — there are always risks when undergoing anesthesia. The procedure knocks you out for only 30 minutes, but allergies and other side effects can happen.</li></ol><p>Other common side effects from the medication may include: menstrual cramps, bloating, anxiety, and moodiness.</p><h3><strong>9. FAQ: Lupron &amp; Ovarian Hyperstimulation Syndrome</strong></h3><p>I had a very high AMH number, so my doctors told me that I would for sure get OHSS. It was one of the reasons why I delayed my egg freezing. My doctor recommended Lupron, an agonist to the traditional trigger shot, which avoids OHSS. I’m not sure what other factors are involved for the doctor to prescribe Lupron over traditional trigger shots. I had no side effects from Lupron that I know of.</p><h3><strong>10. FAQ: Does egg extraction reduce the number of eggs left in me?</strong></h3><p>I got asked this question a lot by friends and family. We all heard that women are born with all the eggs she will every have and every month that reservoir is depleted. The misconception though is that we think only one egg is depleted each month, when in fact it’s more than that. You have about 8–15 follicles across both ovaries and every month, all those follicles start developing eggs. At one point, your body will decide to mature one of them to release into the fallopian tubes. This is probably the body’s mechanism to create redundancy since the egg maturing process is so delicate and important (similar to how millions of sperm are created and then compete for the best one). The remaining eggs during that cycle die off. So every month, you actually use up 8–15 eggs. The egg freezing process simply matures all those follicles and extracts all the eggs that would have died anyways.</p><h3><strong>11. M</strong>iscellaneous<strong> Tips</strong></h3><p><a href="https://alto.com/">Alto Pharmacy</a> is amazing for getting prescriptions delivered same-day. The app and billing are super easy to use, and especially if you are feeling bloated, it saves you a trip to the drugstore.</p><p>If you are afraid of needles, I recommend taking a deep breath in and holding the breath as you inject. It felt very calming for me and also provided the motivation to not back out in that moment.</p><p>For abdominal discomfort, I recommend applying a heated pad.</p><p>Mark your calendar to pay your annual storage fees! Many institutes don’t do automatic billing and especially if you change addresses, make sure you are on top of paying your bills so that they don’t toss your eggs.</p><p>Egg freezing is a deeply personal decision. While it is mostly safe, it does come with some serious potential risks, costly expenses, and discomfort. Results and procedures vary from person to person. Hopefully this guide provided some answers to your questions. Feel free to reach out if you have additional questions.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a4c5d6adea6b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Ivy Natal: Turning Skin Cells into Eggs]]></title>
            <link>https://medium.com/indiebio-sf/ivy-natal-turning-skin-cells-into-eggs-d7174e22ba4e?source=rss-f6e138c7590b------2</link>
            <guid isPermaLink="false">https://medium.com/p/d7174e22ba4e</guid>
            <category><![CDATA[stem-cell-research]]></category>
            <category><![CDATA[fertility]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <dc:creator><![CDATA[Jun Axup]]></dc:creator>
            <pubDate>Tue, 27 Oct 2020 21:50:19 GMT</pubDate>
            <atom:updated>2020-10-27T21:50:19.171Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*R0dNcsvNFHj4dkfjCKy99g.jpeg" /><figcaption>Colin Bortner (left) and Jeff Hsu (right), cofounders of Ivy Natal</figcaption></figure><p><em>The future of our species depends on procreation, but today the world is at an all-time high in infertility due to disease, stress, and the decision to delay having kids. But what if we can generate healthy egg and sperm from your skin cells? Ivy Natal is attempting just that using stem cell technologies and CRISPR. I talked with Ivy Natal cofounders, Colin Bortner and Jeff Hsu.</em></p><p><strong>How did you get interested in the fertility field?</strong></p><p><strong>COLIN:</strong></p><p>That definitely started with Jeff. We are pursuing a revolutionary solution to the problem of the fragility and scarcity of human eggs. Right now, many women can only have children using donor eggs, which has many challenges and obstacles, and donor eggs still don’t allow patients to have a genetic child.</p><p>Our solution pulls together different innovations in synthetic and molecular biology and genetics and genomics to solve this particular problem. Jeff became interested in the problem while working at a pre-implantation genetic diagnosis startup, which was his exposure to the application space, but the underlying approach stems from his interests during his PhD and postdoc research.</p><p>For me, when Jeff and I started talking about the idea, I was very excited by the potential for patients and for society as a whole. Women have always born a disproportionate share of the costs of having children, which has shaped society. Now, effective contraception has been a revolution in giving women the ability to choose to <em>not</em> have a child, but our company has the potential to provide women certainty in their ability to choose <em>to</em> have a child. It’s the flip side of the same coin.</p><p><strong>The science of turning stem cells to eggs has so far only been demonstrated in mice. What bottlenecks do you see for making this possible in people? How do you plan to address those bottlenecks?</strong></p><p><strong>COLIN:</strong></p><p>Yeah, as you say, this has only been done in mice. About four years ago, a team based in Japan published the landmark result in this area. They successfully differentiated stem cells into egg cells, and then they essentially completed IVF cycles with their mice, and those mice gave birth to fertile offspring.</p><p>For a couple of reasons we’re taking a different approach. The first is that a direct translation of the Japanese group’s approach to humans is a non-starter because that would require ovarian tissue from a human fetus. Ovarian tissue from a mouse fetus was a key component of their results. So, part of our motivation is solving that issue.</p><p>So this is a kind of bottleneck, which is legal and ethical but also technical. What we mean by technical is that we don’t have a great way to systematically answer the question: what is the mouse ovarian tissue doing to differentiate the stem cells into egg cells? If we could easily answer that question, we could just emulate whatever variables that matter and get the same results, and by extension we could do the same for humans.</p><p>Now, without getting too deep into the details, our approach works from the inside out instead of from the outside in. Essentially, we’re using different kinds of sequencing technologies to understand the internal state of egg cells, like which genes are being expressed, and then we’re using new tools to directly change the internal state of skin cells to match the internal state of egg cells, and in doing so transforming the skin cell into an egg cell. We’re still in the early stages of proving out this approach for egg cells, but it has worked with a bunch of other cell types.</p><p>The specific engineering challenges in our approach are discovering the genes to turn on or off in order to “reprogram” our skin cells into egg cells, and developing a “safe” tool to do the reprogramming, which eliminates any risk of genome changes. But here we have a huge advantage in that we can work systematically, using sequencing data and computational methods to discover targets and leveraging the synthetic biology ecosystem to do safe reprogramming.</p><p>We already have solutions in place for these challenges, and we are now applying them to a proof-of-concept of our approach, but even if we have setbacks, the long term trends are all working for us. Sequencing is getting better and cheaper, the synthetic biology ecosystem is developing rapidly, and the computational methods we’re using are improving almost monthly. We’re making progress quickly, but even if we did nothing for a year, we’d still end up with more data, lower costs, and better tools.</p><p><strong>If successful, how might your company change the future of childbearing?</strong></p><p><strong>JEFF:</strong></p><p>We’re very focused on the immediate goal, which is helping women who would otherwise rely on donor eggs to have genetic children for the first time. That is a super meaningful problem for us, and reason enough to pour everything into this company. That said, our long term goal is to ensure that every person and couple has the choice to have genetic children. There are hurdles along the way, or problems to solve, but this includes women and men of any age, including those with many conditions which currently complicate reproduction, as well as same-sex couples.</p><p><strong>What lessons have you learned transitioning from scientist to entrepreneur during the IndieBio program?</strong></p><p><strong>JEFF:</strong></p><p>One of the big attractions of becoming an entrepreneur is the freedom to work on problems and solutions you are passionate about. The valley is willing to take a risk on founders with plausible solutions to big problems whereas as a scientist you are often constrained to projects and funding that are often related to your previous work in very obvious and straightforward ways, whether that’s in academia or large corporate research organizations.</p><p>What Ivy Natal is trying to do would be life-altering for many prospective couples and families. That type of impact you can’t measure by publishing metrics or impact factors, and that’s in many ways shifted my own frame of thinking. Since we are developing a process that not only will work but scales to meet the demand of the market, I’ve learned that it doesn’t matter if we execute a protocol myself or work with partners and vendors. What matters is cost, reproducibility, quality of the results, and ability to scale.</p><p>Now, the biggest challenge for me has been transitioning from a fully resourced institution like the Cleveland Clinic to setting up a startup lab in the IndieBio basement. It’s just very different working without the existing physical and human infrastructure of a major research center. In some cases, we’re rebuilding that infrastructure for ourselves and in other cases we’re partnering with vendors to use their infrastructure, almost like cloud computing. For the human infrastructure, we’ve been tapping our existing networks for advice and insights that our team doesn’t have and also working to grow our networks.</p><p>We have the additional complication of relocating and starting up our lab work during the pandemic, but we’ve been able to make a huge amount of progress despite that!</p><p><strong>What does the next year look like for Ivy Natal?</strong></p><p><strong>COLIN:</strong></p><p>Right now, we’re completing a proof of concept for our approach. This involves producing a progenitor of egg cells called primordial germ cells, which will prove out a lot of our core hypotheses and de-risk our business. We want to complete this in Q4 of this year, and next year focus on egg cells. Our timeline for egg cells, how far we’ll get in 2021, depends on some of our ongoing work on our proof of concept. After we have data from those experiments and results from our scaling up partnerships, we’ll have a clearer picture of our progress in the next year.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d7174e22ba4e" width="1" height="1" alt=""><hr><p><a href="https://medium.com/indiebio-sf/ivy-natal-turning-skin-cells-into-eggs-d7174e22ba4e">Ivy Natal: Turning Skin Cells into Eggs</a> was originally published in <a href="https://medium.com/indiebio-sf">IndieBio</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Liberum: Automating Protein Production]]></title>
            <link>https://medium.com/indiebio-sf/liberum-automating-protein-production-1d756d2a9f32?source=rss-f6e138c7590b------2</link>
            <guid isPermaLink="false">https://medium.com/p/1d756d2a9f32</guid>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[protein]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[synthetic-biology]]></category>
            <category><![CDATA[startup]]></category>
            <dc:creator><![CDATA[Jun Axup]]></dc:creator>
            <pubDate>Sun, 25 Oct 2020 19:24:03 GMT</pubDate>
            <atom:updated>2020-10-25T19:24:03.102Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*NWqRdhj4KTBwZkKuz3N6IQ.jpeg" /><figcaption>Aidan Tinafar, CEO of Liberum</figcaption></figure><p><em>When we think of synthetic biology, we often think of synthetic DNA. However, the purpose of the DNA is often to make protein. Today we can order DNA overnight for cheap, but producing protein takes at least two weeks of lab work with various instruments and techniques. Liberum aims to free researchers from the tedious task of turning DNA into protein and make experiments faster and cheaper. I chatted with Liberum’s CEO, Aidan Tinafar.</em></p><p><strong>How important is protein for biological research and production?</strong></p><p>When most people hear the word protein, they immediately think of food. Proteins are far more than food. They are used as therapeutics, industrial catalysts, biomedical research tools, materials for manufacturing and additives in consumer goods just to name a few. Insulin is a protein. Chymosin, the enzyme that enables cheesemaking is a protein. Silk is two proteins combined.</p><p>Imagine if you could come up with a type of material that you could design with vastly diverse physical and chemical properties for a whole host of applications. Ideally, you would want this material to have three properties. First, you would want to be able to make the material from a small set of inputs that are readily available. Second, you would want to be able to control the properties of the material in a tunable or programmable fashion. And third, you would want the production process to be sustainable and capable of being integrated into pre-existing environmentally-friendly modes of production. Protein is that type of material.</p><p>Proteins are strings of building blocks called amino acids that are folded and held together such that they enable certain functions. Combinatorial combinations of 20 amino acids give rise to all the breathtaking diversity we see in nature. The type and order of amino acids are generally encoded within the DNA of an organism. A single cell such as an <em>E. coli</em> bacterium requires a couple thousand different proteins to carry out its biological activity. These proteins can act individually or in concert as networks.</p><p>One way to take advantage of proteins is to piggyback on an existing living organism. For example, we can use yeast to make beer without having to deal with its proteins on a granular level. We can also benefit from extracts, secretions or purified proteins from organisms found in nature.</p><p>In the 70s, we began gaining a grasp on being able to mix and match these wild-type proteins between organisms through somatic fusions and recombinant technologies. During the same decade, chemical synthesis of a complete gene was demonstrated for the first time. Shortly after, in the 80s, polymerase chain reaction (PCR) was invented allowing us to make billions of identical copies of these chemically derived sequences. Together, these technologies enable us to go from a digital DNA sequence stored on a computer to a designer protein within weeks. At Liberum, we significantly speed up this process, so that we can create better products faster.</p><p>These breakthroughs have already brought about the synthetic biology revolution with a total market size worth hundreds of billions of dollars and rapidly growing. For example, the size of the recombinant therapeutics market alone is now over 100 billion dollars. There are two factors that have hidden this revolution in plain sight. Firstly, cultural taboos surrounding genetically modified organisms (GMOs) have incentivized many to categorize these products as natural rather than engineered ones. More importantly, the wide range of applications of these technologies make the market appear highly fragmented. End products include anything from extracts and purified proteins to small molecules, cell lines and other goods and services that use these as intermediates. While apps of the internet revolution came to most through their screens, proteins that lead the synthetic biology revolution touch people’s lives in so many ways that make them hard to categorize as a single class. Massive shifts are often harder to observe.</p><p><strong>What are the bottlenecks in creating protein today and how is your technology solving those bottlenecks?</strong></p><p>Making protein using biology is hard. For every idea, for every iteration, you have to re-engineer the genetics of living cells, grow them, break them open and purify. This process is very hands-on. You need to keep coming back to it over a week or two. The process also requires expertise and expensive equipment that take up a lot of space. Even if you outsource the work to a contract research organization, you are still bound by similar timelines, plus the duration of shipping. Liberum speeds up and automates the protein manufacturing process in a miniaturized device without having the need to re-engineer any living cells. We do it all in a cell-free system that contains the same powerful enzymatic machinery used by cells.</p><p>Now you may wonder, why can we not chemically synthesize these proteins; what is so special about using biology to accomplish protein manufacturing? The problem with chemical synthesis of proteins is really two-fold. First, the error rate for state-of-the-art chemical amino acid incorporation hovers around 1%. This means that for an average bacterial protein of 320 amino acids in length, only about 4% of the final mixture would contain the correct sequence. More importantly, proper folding of amino acid chains into functioning proteins tends to be trickier in chemical systems. A system that more closely resembles biological conditions, such as a cell-free protein expression system, can avoid these problems.</p><p>Technical challenges of making proteins aside, there is a deeper conceptual issue at play. We can certainly make a protein of a specific function starting from a working DNA blueprint, but designing that blueprint is far from trivial. While rational and modular protein designs can be highly informative, they are rarely strictly prescriptive. One often needs to screen sizable libraries of designs to optimize for a specific function. Even if we take wild-type sequences from organisms in nature, there is still room for validation and screening of homologues. Unless and until we have computational means that can predictably design for functionality <em>in silico</em>, protein prototyping remains an indispensable tool for protein engineering.</p><p><strong>How might your company change the way we produce protein?</strong></p><p>We want to enable protein manufacturing at small scale with minimal time and capital investment on the part of our customers. The key insight for our business model is that we have separated the fermentation process from the act of protein production. This allows us to operate as a utility company that delivers protein production capacity to our clients on-demand. Our device and cartridges are merely the last mile. The infrastructure we build to enable this capacity is where much of the value we provide will be generated.</p><p>Once our customers have ordered and amplified their template DNA, they can simply place it inside one of our cartridges and produce their desired protein with a push of a button. Having the capacity in their own labs will allow them to optimize the desired conditions. It also provides control and rapid turnaround to enable more bright ideas to see the light of day.</p><p><strong>What lessons have you learned transitioning from scientist to entrepreneur during the IndieBio program?</strong></p><p>Put the customer first. Science is just the tool we use to serve our customers and the community at large. The value of our company is a function of the value we create for our customers and other stakeholders in the community.</p><p><strong>What does the next year look like for Liberum?</strong></p><p>Rapid iteration cycles to loop in customer feedback has been in our company’s DNA from the very early days. Our goal over the next year is to build our infrastructure such that we can bring the power of cell-free protein expression to thousands of labs around the world at very affordable prices. We will continue to build upon enhancing user experience through further iterations of the device and cartridges. Our goal is to wrap up alpha and beta testing as soon as possible so that we can launch our product within the next year.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1d756d2a9f32" width="1" height="1" alt=""><hr><p><a href="https://medium.com/indiebio-sf/liberum-automating-protein-production-1d756d2a9f32">Liberum: Automating Protein Production</a> was originally published in <a href="https://medium.com/indiebio-sf">IndieBio</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Dalton Bioanalytics: comprehensive molecular analysis]]></title>
            <link>https://medium.com/indiebio-sf/dalton-bioanalytics-comprehensive-molecular-analysis-d4e157a51fbc?source=rss-f6e138c7590b------2</link>
            <guid isPermaLink="false">https://medium.com/p/d4e157a51fbc</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[wellness]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Jun Axup]]></dc:creator>
            <pubDate>Sun, 02 Feb 2020 21:02:53 GMT</pubDate>
            <atom:updated>2020-02-02T21:02:53.735Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/691/1*fsqSnpCk5Hd7yk3FZeaufw.jpeg" /><figcaption>Dalton Bioanalytics cofounders Austin Quach (left) and Seungjun Yeo (right)</figcaption></figure><p>Our blood and cells are complex mixtures of DNA, RNA, proteins, metabolites, lipids, sugars, metal ions, and more. All of these are deeply important in informing our health and wellness. Today, we can measure a few of these molecules routinely, but what are we missing might be in the rest of the data. Dalton Bioanalytics is creating a comprehensive and inexpensive method to look at all these molecules to bring about truly multiomics data.</p><p>I sat with Austin Quach, CSO of Dalton Bioanalytics, to talk about his platform from inventing it in his lab to starting a company.</p><p><strong>How did you become interested in multiomics?</strong></p><p>Why are we waiting for disease to strike before treatment? Why do we continue to treat patients using one-size-fits-all? These questions were really the seeds that led to our interest in multiomics. What it boils down to is that we lack the quantity and quality of data to make early detection and precision medicine really successful. There’s a ton of information beyond each person’s genetics including their age, sex, ethnicity, dietary and lifestyle habits, exposure to drugs, medications, pollutants, and infections, tissue, organ, and psychosocial health, etc. The only way to really automatically capture most of this information is to integrate multiple layers of bioinformation — a.k.a. multiomics. For example, genomics (DNA), transcriptomics (RNA), proteomics (proteins), microbiomics (microbes), metabolomics (metabolites), and exposomics (exposures), etc.</p><p>Unfortunately, current multiomic approaches are prohibitively expensive. In fact, many have tried to push this approach forward only to realize that it is too expensive to scale. This is when things really got interesting for us — what if we could invent a way to do multiomics using a single low cost assay? The performance specs might not be as good as the individual specialized -omics assays but we might be able to hit that sweet spot where we capture enough data to become invaluable but still maintain affordability. It was basically like that aha moment when you realize what makes smartphones so great: they may not be as good as specialized tools but who has the time and energy to lug around a backpack full of expensive equipment?</p><p><strong>How did you decide to start the company and how does your team come together?</strong></p><p>After about a year of tinkering in the lab with the goal of developing an all-in-one assay, we managed to pull off an amazing technical feat: for the first time in history we had developed an assay that was capable of measuring all major types biochemicals in a single run. I decided that the quickest route to use technological advance to benefit society was to start a company and commercialize it. With early guidance from the IndieBio team, I began my cofounder search and shortly after I met Seungjun who at the time was building his own company developing AI to help diagnose prenatal congenital heart disease from ultrasound imaging. We quickly realized that we were essentially working towards the same goal of helping people through early detection and we founded Dalton Bioanalytics to pursue this mission.</p><p><strong>How does your technology work? What was the key insight?</strong></p><p>We invented a new way to use existing analytical instrumentation — tried-and-true high resolution liquid chromatography mass spectrometry — to analyze proteins, lipids, electrolytes, nucleic acids, carbohydrates, metabolites, and other small molecules using a single laboratory procedure. It’s really a Frankenstein of modern bioanalytical techniques. The key insight was that if we could somehow get all of the different types of misbehaving molecules to behave well, we might have a shot at analyzing everything in a single run. This ended up taking 6+ corequisite techniques to get it to really come to life — take out any of these and the assay is severely compromised. It’s easy to understand why most experts believe what we’ve accomplished is impossible — it basically looked like it wasn’t working until finally it worked.</p><p><strong>What lessons did you learn transitioning from science to entrepreneur at IndieBio?</strong></p><p>Coming from a science background it was interesting to see the stark differences in culture between science and business, and even between business and the startup world. There were a few key lessons that I learned transitioning from science to entrepreneurship: 1) the primary goals of communication are different — in science it’s about being detailed and technically accurate whereas in a pitch it’s really about distilling the most important parts — the details can be delved into later, 2) in this vein, cool technological firsts by themselves have value in science but in entrepreneurship it’s really about executing on creating real-world solutions to problems that people are willing to pay for, and 3) though this is gradually changing, it’s not uncommon for a lone researcher to pull off something great in science. In building a company on the other hand, there’s simply too much to do, across too wide a skillset. In essence, science can be played as a solo game, but startups are a team sport.</p><p><strong>How do you think your success as a company will change healthcare?</strong></p><p>If everything goes according to plan, we’ll build a self-sustaining research platform from which we can continue to develop new and improved algorithms biomarkers that plug into our multiomic data. Over time, this means we’ll be able to create an affordable semi-annual liquid biopsy analysis for early detection of most diseases and conditions. As the system continues to develop, there will also be opportunities for data-driven drug development and precision medicine.</p><p><strong>What milestones are in the near future?</strong></p><p>In the near-term, our milestones are to build out our commercial laboratory with state-of-the-art instrumentation, to optimize our assay for maximum sensitivity, coverage, &amp; throughput, and to launch our multiomic analysis platform for the research community. We’re currently working on several models for engaging with researchers ranging from simple research as a service to more exciting co-development partnerships.</p><p><em>Watch Dalton Bioanalytics’</em> <em>pitch on </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-feb-6-2020-at-herbst-theater-tickets-85186201221"><strong><em>IndieBio Demo Day</em></strong></a><em>, Thursday February 6th, 2020 in San Francisco or via LiveStream. </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-feb-6-2020-at-herbst-theater-tickets-85186201221"><strong><em>Register here</em></strong></a><em>!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d4e157a51fbc" width="1" height="1" alt=""><hr><p><a href="https://medium.com/indiebio-sf/dalton-bioanalytics-comprehensive-molecular-analysis-d4e157a51fbc">Dalton Bioanalytics: comprehensive molecular analysis</a> was originally published in <a href="https://medium.com/indiebio-sf">IndieBio</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Pando Nutrition: Eliminating antibiotics from our food]]></title>
            <link>https://medium.com/indiebio-sf/pando-nutrition-eliminating-antibiotics-from-our-food-7e86fa39fb6e?source=rss-f6e138c7590b------2</link>
            <guid isPermaLink="false">https://medium.com/p/7e86fa39fb6e</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[synthetic-biology]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[agriculture]]></category>
            <dc:creator><![CDATA[Jun Axup]]></dc:creator>
            <pubDate>Tue, 28 Jan 2020 23:19:04 GMT</pubDate>
            <atom:updated>2020-01-28T23:19:04.468Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/960/1*e87K7B2ux19h4RL4u0mYJg.jpeg" /><figcaption>Pando Nutrition cofounders Doug Manofsky (left) and Craig Rouskey (right).</figcaption></figure><p>Antibiotics, hormones, and additives in livestock feed help animals grow, but are not great when they end up on our dinner plates. The US FDA banned the use of antibiotics in 2017, but antibiotics are still widely used in the industry because there are very few alternatives available. Pando Nutrition is challenging the paradigm by genetically engineering probiotics to promote the health of animals through a healthy microbiome. In doing so, they can keep the benefits of antibiotics and eliminate the downsides.</p><p>I interviewed co-founders Doug Manofsky (CEO) and Craig Rouskey (CSO) about their entrepreneurial journey.</p><p><strong>How did you become interested in synthetic biology and agtech?</strong></p><p>DOUG: I have always been a very curious person. My father was an engineer that worked at NASA and he encouraged my siblings and I to tinker from a young age. I was constantly building things from computers to paintball guns. I would eventually pursue a degree in mechanical engineering where computers evolved into electric cars. Around this time, I started to ask bigger questions. How do we end hunger? How can we cure the toughest diseases? How can we reduce pollution? I quickly realized that at the center of some of the biggest problems facing us today is biology. We are biological humans that eat biological food and live on a biological planet. If I wanted to change the world, I needed an incredibly talented co-founder with biological skills, and if we wanted to move the needle in a meaningful way, we needed to build a big business with big impact.</p><p>CRAIG: I have been interested in science since I was a young child. It wasn’t until I met my undergraduate mentor, Sr. Maryanne Jerkofsky, that I really solidified my path into science. After my graduate work in Molecular Biology and Immunology, I worked in industry and really honed my synthetic biology skills. I found that there was something really beautiful about the way we could manipulate the molecular world into performing what we need it to do. I fell in love with it. This would have been in 2005. The application of synthetic biology has led me down many paths, co-founding Real Vegan Cheese, the GETit Project, and BioNascent. The idea that I could apply my skills to help the world really excited me, and here I am today applying this technology to helping the world via agtech, all led by an amazing co-founder, Doug Manofsky.</p><p><strong>How did you decide to start the company and how does your team come together?</strong></p><p>DOUG: Back in 2017, Craig and I were both actively researching big problems to solve and it was a little bit serendipitous that we met when we did. I was interested in Craig’s work at his previous startup, BioNascent, and I wanted to know what was next for him. We started talking about big problems and the new solutions that could be used. We brainstormed tons of ideas together. We realized that the microbiome was going to revolutionize therapeutics and nutrition. At the advice of some mentors, we began looking into animal nutrition. That’s when we discovered that the microbiome was the perfect solution for the huge antibiotic issue in livestock production, not to mention a huge platform to improve livestock sustainability.</p><p>CRAIG: I’ll never forget the day Doug called me in November, 2017. I was working at Novartis and he was curious about my work with BioNascent. I told him about the regulatory roadblocks we faced and he and I devised a plan to do similar work in animals to validate the technology. We’ve since taken a long road to finding the sweet spot where our science and business minds align perfectly with our collective passion to help the world.</p><p><strong>How does your technology work? What was the key insight?</strong></p><p>DOUG: Our technology leverages the power of the microbiome. We realized that the microbiome is central to health and nutrition in all animals, even humans. By using tried and true genetic techniques, the microbiome can be supercharged to solve some of the worlds biggest challenges in hunger, disease, and pollution.</p><p>CRAIG: Early in our conversations in 2017, Doug and I had what I would call the ‘Ah-Ha! Moment.’ We realized that the most difficult piece of what people are trying to do in complex protein manufacturing is the purification step. We realized that would could bypass this step and deliver high-value molecules directly to the microbiome, significantly decreasing the costs associated with supporting animal health. This moment was fundamental in shaping the company today.</p><p><strong>What lessons did you learn transitioning from science to entrepreneur at IndieBio?</strong></p><p>DOUG: I made the transition from science to business after undergraduate, but that was nowhere near sufficient to prepare me for entrepreneurship. The IndieBio team helps us navigate the intricacies of raising venture capital, telling a compelling story and building a great team.</p><p>CRAIG: In being a practicing scientist for what is nearly half of my life I’ve learned to value the art of questioning…everything. I’ve been through IndieBio twice now, and it both experiences I’ve learned the value of applying that scientific questioning to a business. That is, in both science and business, we are pushed to challenge our assumptions, and validate what we believe to be true. This is crucial to science. It’s crucial to business.</p><p><strong>How do you think your success as a company will change the animal feed industry?</strong></p><p>DOUG: We hope that our success in the animal feed industry will benefit people, the planet, and the animals. By reducing antibiotic usage, we hope to prevent antibiotic resistant disease from sickening people through our food. By leveraging the microbiome, we hope to benefit the planet with fewer greenhouse emissions, such as methane from cows. We also hope that our solutions will help the animals live healthy, happy lives.</p><p>CRAIG: I think what we are doing has amazing potential to change the world. I suppose that if I didn’t believe that, I wouldn’t be building Pando. From helping to preserve antibiotics as valuable assets for human use, to reducing methane production in cattle, Pando will help shape a more sustainable livestock-rearing future. The applications are broad, and the outcomes of our first few products will pave the way for future technologies in the animal health and human health spaces.</p><p><strong>What milestones are in the near future?</strong></p><p>DOUG: We are seeking partners across the industry to help us make our solution a reality. From manufacturers, to distributors, to major food companies, we need lasting partnerships make a big impact.</p><p>CRAIG: As the CSO, my focus is mostly on our scientific milestones and how they support our business. These milestones include continuing to develop our platform, work on securing partnerships to co-develop technologies for animal health, scaling our technology in efficient ways, and of course, pursuing some clever ways to enhance our products.</p><p><em>Watch Pando Nutrition’s</em> <em>pitch on </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-feb-6-2020-at-herbst-theater-tickets-85186201221"><strong><em>IndieBio Demo Day</em></strong></a><em>, Thursday February 6th, 2020 in San Francisco or via LiveStream. </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-feb-6-2020-at-herbst-theater-tickets-85186201221"><strong><em>Register here</em></strong></a><em>!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7e86fa39fb6e" width="1" height="1" alt=""><hr><p><a href="https://medium.com/indiebio-sf/pando-nutrition-eliminating-antibiotics-from-our-food-7e86fa39fb6e">Pando Nutrition: Eliminating antibiotics from our food</a> was originally published in <a href="https://medium.com/indiebio-sf">IndieBio</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[BiomeSense: the Future of Microbiome is Data]]></title>
            <link>https://medium.com/indiebio-sf/biomesense-the-future-of-microbiome-is-data-65db53ff3bb3?source=rss-f6e138c7590b------2</link>
            <guid isPermaLink="false">https://medium.com/p/65db53ff3bb3</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[microbiome]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[Jun Axup]]></dc:creator>
            <pubDate>Fri, 21 Jun 2019 01:16:02 GMT</pubDate>
            <atom:updated>2019-06-21T01:16:02.495Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ZWQipMUPjGQ8tW9UCv7LSg.jpeg" /><figcaption>Dylan Nichols and Kevin Honaker (CEO, co-founder) of BiomeSense</figcaption></figure><p>The microbiome is extremely exciting, but today it is still a black box of mystery. In order to really harness the therapeutic potential of the microbiome, we need to have more data, and preferably longitudinal data every single day. This is because the critical data is in the way the microbiome changes.<a href="http://biomesenseinc.com/"> BiomeSense</a> is making a system to collect this valuable data with a combination of hardware and low-cost assays, allowing them to capture the most comprehensive data for the microbiome industry.</p><p>I sat down with Kevin Honaker, CEO of BiomeSense.</p><p><strong>How did you become interested in the microbiome?</strong></p><p>I’ve been interested in the concept of precision medicine for a long time. The idea of using individualized data for health has always appealed to me because it’s so simple and obvious, yet can have such a huge impact, which I saw firsthand in my last job at a pharmacogenomics start-up. So, when I first started to learn about the microbiome, I saw its great potential as the next wave of precision medicine, and that’s how my interest grew and I decided it was a space I wanted to pursue.</p><p><strong>How did your team come together to start this company?</strong></p><p>The initial co-founders of the company were myself and the scientific microbiome lead, Dr. Jack Gilbert, who at the time was a Professor at the University of Chicago. Jack is a world expert in microbiome research, he’s published hundreds of papers and founded American Gut and the Earth Microbiome Project. Through all this work, he realized that the microbiome changes very rapidly, and if we’re not capturing that data, it’s virtually impossible to really understand what’s going on. Over the years he’s tried many different ways to get more data, but none of them really worked — too expensive and hard to get the patients to use them. So, for years he’s been sitting on this and trying to build a tool to enable this time longitudinal data.</p><p>I got connected to him in late 2017 while working with the University of Chicago’s technology commercialization team. At the same time we recruited Dr. Savas Tay, a microfluidics expert at the University of Chicago because we needed to build a “lab-on-chip” to make this possible. So, we had the microbiome and engineering expertise from them, then I provided the commercial input, and with that team we started the business in 2018.</p><p><strong>How does your technology work? What are the key insights?</strong></p><p>Today, the vast majority of microbiome data is acquired via collecting and processing stool samples in a lab. The problem is this is very expensive on a per-sample basis, and more importantly, patients hate doing it — we’ve seen &lt;40% adherence to a single stool sample request! To get more frequent data, you need to address both of those issues.</p><p>So, we’ve built a proprietary biosensor that is essentially an automated wetlab that you install in your bathroom. A part of the device is embedded into any toilet and passively collects a small stool sample every time the patient uses the bathroom, so they don’t even have to interact with it at all. This sample is passed to an advanced microfluidic system that processes it to isolate the microbial DNA. Some of that DNA is stored for downstream sequencing and the rest passed to our screening assay which provides a low-cost microbiome readout automatically.</p><p>This required some pretty advanced engineering, but luckily we have an extremely prestigious team of scientists and engineers that helped us put it all together!</p><p><strong>What has been some of your biggest learnings while at IndieBio?</strong></p><p>One of the first things you hear here is the idea of sales, sales, sales and how that solves all problems. I initially thought to myself, “We can’t sell this — we’re still a year away from having a finished product!” Still, I figured it couldn’t hurt to try. So we did, and the customer response was so overwhelming that within weeks we filled up our launch pilot program, and even had to turn down another five studies. We’re going to be working with Mayo Clinic, Harvard’s Dana-Farber, University of Chicago, UCSF, to name a few. The response we got helped validate the need for our solution. The idea of being able to do that earlier than you might think was my key learning.</p><p><strong>How do you think the success of your company will change the microbiome industry?</strong></p><p>I believe we’ll completely re-shape how the microbiome is used and understood. Today, we barely understand the microbiome — every other day you read article linking the microbiome to all kinds of health conditions, but when you ask how it does that and why it does that, no one can answer. The one microbiome treatment we have is fecal microbiota transplant to cure C. difficile, and yet people have absolutely no idea how or why it works.</p><p>Evidence is mounting that the problem is we’ve dramatically underestimated how clinically important short-term changes in the microbiome are. Today, we essentially can’t see them because we can’t sample frequently enough, so they’ve been ignored — out of sight, out of mind. But new studies are coming out showing that when you sample far more frequently, you can discover more trends and patterns and start to figure out how the microbiome works, not just that it does.</p><p>This means we’ve really barely scratched the surface of the discovery potential of the microbiome — these changes are incredibly important for understanding how the body and microbiome interact to alter health, yet we’ve never explored them. By changing that, we’ll dramatically reshape the landscape of microbiome research and in the near future collecting daily data will become the “norm” in research.</p><p><strong>What milestones are in your near future?</strong></p><p>In the past 4 months, we’ve got a bunch of pilot customers, built a functioning MVP, and expanded the team. So, our next milestone is simple — use our biosensor in clinical trials and start generating data. We’re starting to finalize designs for manufacturing and should be in our pilot’s hands within 12 months. Once that’s done, we’ll start scaling up our analytics and data pipeline, to start building the world’s largest and most valuable microbiome database — and the only one with time-series data. Long-term, this data will enable scientists to observe, understand, and eventually treat microbiome conditions to improve the health of patients.</p><p><em>Watch BiomeSense</em> <em>pitch on </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-june-25-2019-at-herbst-theater-tickets-59849901667"><strong><em>IndieBio Demo Day</em></strong></a><em>, Tuesday June 25th in San Francisco or via LiveStream. </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-june-25-2019-at-herbst-theater-tickets-59849901667"><strong><em>Register here</em></strong></a><em>!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=65db53ff3bb3" width="1" height="1" alt=""><hr><p><a href="https://medium.com/indiebio-sf/biomesense-the-future-of-microbiome-is-data-65db53ff3bb3">BiomeSense: the Future of Microbiome is Data</a> was originally published in <a href="https://medium.com/indiebio-sf">IndieBio</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[11BIOMICS: Rebalancing Ecosystems to Fight Plant Diseases]]></title>
            <link>https://medium.com/indiebio-sf/11biomics-rebalancing-ecosystems-to-fight-plant-diseases-cc702d75845c?source=rss-f6e138c7590b------2</link>
            <guid isPermaLink="false">https://medium.com/p/cc702d75845c</guid>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[agriculture]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[marijuana]]></category>
            <dc:creator><![CDATA[Jun Axup]]></dc:creator>
            <pubDate>Tue, 18 Jun 2019 18:24:07 GMT</pubDate>
            <atom:updated>2019-06-18T18:24:07.721Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*HMz1K5oF_Z7Be-CoiPgk1w.jpeg" /><figcaption>Siv Watkins and Jeff Holland, cofounders of 11BIOMICS</figcaption></figure><p>Plants live in symbiosis with the microbes and fungi in their environment. When this balance is disrupted, it can lead to diseases. <a href="https://www.11biomics.com/">11BIOMICS</a> is rebalancing ecosystems to fight off plant diseases, such as powdery mildew on cannabis plants. Their microbial spray not only treats the disease, but can also prevent it.</p><p>I chatted with Siv Watkins, CEO of 11BIOMICS, about her transition from academic scientist to entrepreneur.</p><p><strong>How did you become interested in microbiological research?</strong></p><p>When I was little I was a gross little child and used to read a lot about horrible diseases and plagues, and that’s when I started to learn about bacteria and viruses. When I grew up and started to discover the broader impact of microbiology, I was consistently astonished by what microbes can do, and how they structure life on this planet. It became pretty clear to me that in some ways, human scientists were approaching industrial microbiology the wrong way — and rather than trying to make them do things they weren’t used to, we should be mimicking what microbes already do in the natural world.</p><p><strong>How did you decide to start the company and how does your team come together?</strong></p><p>Before we started this company I was a successful academic scientist, and I loved teaching but I was feeling increasingly frustrated with and restricted by the academy. After a very rough semester I decided to leave my academic job for the good of my soul, and since I needed a new job we decided to start 11BIOMICS.</p><p>My co-founder, Jeff, and I have been extremely close friends for a long time, and through his work as a therapist and addictions specialist, and my background as a mental health advocate in the sciences, we started interacting with the medical cannabis industry in New Mexico, particularly the growers. That’s when we realized that making good medicine from cannabis requires good science. And here we are.</p><p><strong>How does your technology work? What was the key insight?</strong></p><p>The medicinal benefits of cannabis, whether we’re talking hemp or marijuana, are a product of a healthy plant. You can’t make high quality medicine from a sick plant. Cannabis today is so overbred and is grown in extremely high density environments, which means pest control is a huge problem. Every single grower in the US is engaged in a constant battle with insect and fungal pests. And they’re all using the same ineffective and potentially harmful treatment methods, which means we’re observing, in real-time, the evolution of very resistant pests. This is actually a problem in agriculture generally — the development of resistance to pesticides and things like azoles represents a real, immediate threat to food security and public health. So there’s not much point to escalating the situation with even nastier chemicals.</p><p>Instead, we look to what happens in nature. Wild cannabis, growing on the side of a mountain somewhere, is much better at defending itself against diseases and pests. Why? Plants in the wild recruit microbes to fight disease on their behalf. These microbes are highly specific — they’ve evolved and grown in collaboration with the plant for the entirety of it’s existence. We mimic this process — find the microbes specifically associated with that plant that can fight diseases and pests on its behalf, grow them up, and return them to the plant at therapeutic levels. Our method is highly targeted to specific plant species (so it’s very effective), it doesn’t promote resistance (we isolate many different microbes and periodically switch them up) and it doesn’t rely in any way on the introduction of chemicals to a crop.</p><p><strong>What lessons did you learn transitioning from science to entrepreneur at IndieBio?</strong></p><p>I had to let go of my desire for perfection very quickly, which was a real challenge for someone coming from such a detail-oriented background. But it was also truly refreshing to have the freedom to be so creative. I was able to reconfigure my focus on just always moving forward, always making progress, always building. I have always loved tinkering and prodding and poking in the lab — just doing stuff for the sake of curiosity and to see what would happen. Four months in the IndieBio lab has been the equivalent of extreme tinkering.</p><p><strong>How do you think your success as a company will change the cannabis industry?</strong></p><p>We’ve demonstrated very clearly that our proof of concept works for treating fungal diseases on hemp and cannabis — and we have sales to show it. We’re now working on figuring out how to do the same thing for insects. Cannabis is a really important crop for lots of reasons, but we really want to be able to bring this approach to other large-scale agricultural crops for obvious reasons: an effective, naturally-derived alternative to pesticides. I think we can make a huge difference with the right collaborators — we could be looking at an absolute paradigm shift in how the world looks at sustainable food security.</p><p><strong>What milestones are in the near future?</strong></p><p>From our home in New Mexico we’re working with existing and new customers to provide integrated pest management programs for commercial cannabis and hemp growers of all kinds. After we’ve raised our seed funding we’re going to expand our scientific team to kick our R&amp;D in to overdrive, and based on the huge amount of data we’re producing already, we want to produce the first cannabis-specific biopesticide to be regulated by the EPA.</p><p><em>Watch 11BIOMICS</em> <em>pitch on </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-june-25-2019-at-herbst-theater-tickets-59849901667"><strong><em>IndieBio Demo Day</em></strong></a><em>, Tuesday June 25th in San Francisco or via LiveStream. </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-june-25-2019-at-herbst-theater-tickets-59849901667"><strong><em>Register here</em></strong></a><em>!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=cc702d75845c" width="1" height="1" alt=""><hr><p><a href="https://medium.com/indiebio-sf/11biomics-rebalancing-ecosystems-to-fight-plant-diseases-cc702d75845c">11BIOMICS: Rebalancing Ecosystems to Fight Plant Diseases</a> was originally published in <a href="https://medium.com/indiebio-sf">IndieBio</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[New Culture: Cheese Without Cows]]></title>
            <link>https://medium.com/indiebio-sf/new-culture-cheese-without-cows-eb1fdf5e86bf?source=rss-f6e138c7590b------2</link>
            <guid isPermaLink="false">https://medium.com/p/eb1fdf5e86bf</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[food]]></category>
            <category><![CDATA[cheese]]></category>
            <category><![CDATA[vegan]]></category>
            <category><![CDATA[future-of-food]]></category>
            <dc:creator><![CDATA[Jun Axup]]></dc:creator>
            <pubDate>Mon, 17 Jun 2019 03:07:05 GMT</pubDate>
            <atom:updated>2019-06-17T03:07:05.937Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vB5S58OynV3uE6FXWiLwuA.jpeg" /><figcaption>From left: Shalini, Dilraj, Becky, Inja (CSO, cofounder), and Matt (CEO, cofounder) of New Culture</figcaption></figure><p>The exciting industry of meat alternatives is moving us towards cleaner foods for planetary and human health. But no animal causes more methane emissions than the dairy cow. Cheese alternatives traditionally have missed the mark on taste and texture because they lack casein proteins found in milk. <a href="https://www.newculturefood.com/">New Culture</a> is creating a new way to produce the same casein proteins in bacteria to make delicious animal-free cheese.</p><p>I talked with New Culture’s CEO, Matt Gibson.</p><p><strong>How did you become interested in cellular agriculture?</strong></p><p>I first heard about cellular agriculture with the news of the world’s first lab grown beef patty in 2013 that was developed by Mark Post. I was already a vegan by that stage and was blown away by the concept of lab grown meat. I remember thinking how much of the world’s problems could be alleviated if this technology reaches scale, especially the most important matter of our time — climate change.</p><p><strong>How did you decide to start the company and how does your team come together?</strong></p><p>After seeing Mark Post’s patty, I wanted to find anyone in New Zealand that was doing something similar. I tried contacting a whole bunch of people including professors and business leaders to see if they knew of anyone working on this locally but I got absolutely no response. So I sat on the sidelines for a few years thinking that this would be a movement I’d likely miss out on. I continued watching the space grow with more companies arriving on the scene and I decided that rather than wait to find a cell ag company to join, I’d start one myself.</p><p>I had seen a lot of cell-ag companies working on meat but hardly anyone working on dairy. Being from New Zealand, where dairy is our biggest export, I’d not only seen how damaging this industry can be but also knew a lot about it. It seemed to me to be the logical choice to jump into an underdeveloped space I knew a bit about.</p><p>I remember speaking to some other company founders about how they found their co-founders. I was given the advice to go ‘full-on’ recruiter mode, buy LinkedIn premium and search for exactly the type of co-founder I was looking for. I reached out to a lot of people and after a lot of interviews and a few months I found Inja and Arie, my co-founders.</p><p><strong>How does your technology work? What was the key insight?</strong></p><p>Our first focus is cheese, we found out very early on that the key component of dairy cheese that gives it the traits that everyone loves are the casein proteins. This is actually why I believe plant based cheeses can never replace dairy cheese as they don’t have those casein proteins which are extraordinarily unique, only being found in mammalian milk and are extraordinarily important for cheesemaking.</p><p>As we obviously don’t want to source our casein proteins from animals, we are using what is known as recombinant protein technology to produce them. This works by instructing a microbe to produce our target protein through fermentation. We then combine this protein with plant based fats and sugars to make sustainable and ethical dairy cheese with no lactose and no cholesterol.</p><p><strong>What lessons did you learn transitioning from science to entrepreneur at IndieBio?</strong></p><p>I never really considered myself as just a scientist. When I went to university, I wanted to do both science and business. Wanting to pick just one to study, I figured it would be best to learn business by myself and I should study science. The act of deciding to do business by myself actually stopped me from continuing my science studies into the postgrad level. I had founded a company while studying which I went into full time after graduating with a BSc in microbiology and genetics.</p><p>In that sense, I don’t think I ever was one or the other with regards to a scientist or an entrepreneur. I like to think of myself as always being both. To me the most important aspects of science that I use in business is critical thinking.</p><p><strong>How do you think your success as a company will change the cheese industry?</strong></p><p>In short, it will make it more sustainable and more ethical. It will also make people consider the sustainability of the cheese they are currently eating, as cheese is the most unsustainable of all dairy products, which a lot of people are not aware of.</p><p><strong>What milestones are in the near future?</strong></p><p>We are currently raising a seed round which we hope to close very soon. After that we want to begin scaling up our cheese production and make our first 100g hand-made ball of recombinant mozzarella cheese.</p><p><em>Watch New Culture pitch on </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-june-25-2019-at-herbst-theater-tickets-59849901667"><strong><em>IndieBio Demo Day</em></strong></a><em>, Tuesday June 25th in San Francisco or via LiveStream. </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-june-25-2019-at-herbst-theater-tickets-59849901667"><strong><em>Register here</em></strong></a><em>!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=eb1fdf5e86bf" width="1" height="1" alt=""><hr><p><a href="https://medium.com/indiebio-sf/new-culture-cheese-without-cows-eb1fdf5e86bf">New Culture: Cheese Without Cows</a> was originally published in <a href="https://medium.com/indiebio-sf">IndieBio</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Guided Clarity: Boosting Energy & Longevity]]></title>
            <link>https://medium.com/indiebio-sf/guided-clarity-boosting-energy-longevity-2ccd59db7b37?source=rss-f6e138c7590b------2</link>
            <guid isPermaLink="false">https://medium.com/p/2ccd59db7b37</guid>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[entrepeneurship]]></category>
            <category><![CDATA[longevity]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[Jun Axup]]></dc:creator>
            <pubDate>Tue, 11 Jun 2019 21:18:01 GMT</pubDate>
            <atom:updated>2019-06-11T21:27:47.073Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*xTVFuwsEe5Ieb3-peoOjgA.jpeg" /><figcaption>Olof (left) and Helen (right), co-founders of Guided Clarity</figcaption></figure><p>It is becoming more and more clear that food is medicine. The nutrients we eat everyday not only nurture us, but keeps us healthy. <a href="http://gclarity.com/">Guided Clarity</a> found an ingredient in mother’s milk that helps to increase metabolism and longevity by targeting the mitochondria, the powerhouse of the cell. Now, the team is turning it into a medical food.</p><p>I chatted with Helen Chen, CEO of Guided Clarity, about her entrepreneurial journey.</p><p><strong>How did you become interested in healthy aging research?</strong></p><p>I’ve always been fascinated about how bioactive molecules exist in nature and how they can be used for our wellbeing. Historically the discovery of new compounds in nature has had a medicinal focus trying to treat diseases. I think there is a great untapped potential in finding molecules that can strengthen our health into old age. While working on another research project, I came across unique compounds from mother’s milk that can naturally rejuvenate cells. That’s how I stumbled into healthy aging research.</p><p><strong>How did you decide to start the company and how does your team come together?</strong></p><p>I wanted to start a company that mimicked the natural processes in nature and recreating them in a scientific and precise way. In other words, being guided by nature in the discovery process, and having scientific clarity in the development process. Hence, the name Guided Clarity. My team came together through former colleagues whom I had worked with, spanning from food innovations to drug development. They are equally excited to derive active compounds from nature for health benefits.</p><p><strong>How does your technology work? What was the key insight?</strong></p><p>Ineffective metabolism and chronic inflammation are two important drivers of aging. Our technology works by targeting the mitochondria, a tiny cellular structure that’s responsible for metabolism and inflammation. There are many approaches to improve or increase the number of mitochondria, such as exercise, to combat aging. Our key insight is that instead of repairing the mitochondria to improve its performance, nature’s way is to get rid of old dysfunctional mitochondria which improves the cellular environment in general. The technology is based on the important finding that there are certain molecules in mothers’ milk that stimulate mitochondrial renewal.</p><p><strong>What lessons did you learn transitioning from science to entrepreneur at IndieBio?</strong></p><p>I learned how crucial it is to remain practical and pragmatic about translating science into a product. Science is largely attempting to explain our world, while the goal of our product is to improve health. I learned to prioritize scientific endeavors that translate into business milestones and de-risk the company. The second learning is the importance of scientific story telling — we always do a better job on how to describe science in an understandable and accessible way.</p><p><strong>How do you think your success as a company will change the healthcare industry?</strong></p><p>We want to create and be part of the new movement in medical foods — finding novel natural molecules using rigorous pharmaceutical methods, that can bring tangible health impact to people. It will be part of the next generation of integrative healthcare, where precise nutrients are used for effective disease management. We’d also like expand the ways in which medicine can be developed — using natural molecules in small scale medical food clinical studies to identify indications and responders. This approach is fraction of the cost compared to pharmaceutical clinical trials. While these molecules will still need to meet drug requirements, their chances of actually reaching and benefiting patients will improve drastically.</p><p><strong>What milestones are in the near future?</strong></p><p>We will transition to a pilot production plant within the next six months, which will provide enough samples for market testing and clinical studies. Within one year, we will complete multiple healthy aging clinical studies.</p><p><em>Watch Guided Clarity</em> <em>pitch on </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-june-25-2019-at-herbst-theater-tickets-59849901667"><strong><em>IndieBio Demo Day</em></strong></a><em>, Tuesday June 25th in San Francisco or via LiveStream. </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-june-25-2019-at-herbst-theater-tickets-59849901667"><strong><em>Register here</em></strong></a><em>!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2ccd59db7b37" width="1" height="1" alt=""><hr><p><a href="https://medium.com/indiebio-sf/guided-clarity-boosting-energy-longevity-2ccd59db7b37">Guided Clarity: Boosting Energy &amp; Longevity</a> was originally published in <a href="https://medium.com/indiebio-sf">IndieBio</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[New Age Meats: Leading a Cultural Shift in Protein Production]]></title>
            <link>https://medium.com/indiebio-sf/new-age-meats-leading-a-cultural-shift-in-protein-production-2b48dde66fc?source=rss-f6e138c7590b------2</link>
            <guid isPermaLink="false">https://medium.com/p/2b48dde66fc</guid>
            <category><![CDATA[stem-cells]]></category>
            <category><![CDATA[future-of-food]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[food]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <dc:creator><![CDATA[Jun Axup]]></dc:creator>
            <pubDate>Tue, 06 Nov 2018 18:37:43 GMT</pubDate>
            <atom:updated>2018-11-06T18:48:42.231Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*sO46DYwea9lO360_8KY2cA.jpeg" /></figure><p>Cell-based meats, or clean meats, can alleviate pressures on the environment, end animal suffering, and produce sustainable protein for the growing world population. Yet, we are still far away from making cell-based meats a reality due to technological challenges. <a href="http://newagemeats.com/">New Age Meats</a> is tackling these challenges with automation and data to accelerate product development and bring pork sausages to market sooner. We chatted with Brian Spears, CEO of New Age Meats.</p><p><strong>How did you become interested in the cell-based meat field?</strong></p><p>I left my last company because — although it was extremely interesting, with great customers and cool technology — it wasn’t having a tremendous social impact. I’ve always believed in having a social impact mission. During my time at that company, I started other nonprofits, but they typically got the dregs of my time and energy. So, my conviction has been that your company should be a vehicle for how you see the world. I sold my ownership of that company, I’m still on great terms with my former co-founder, but I needed a technology or industry that was benefiting from this three-way collision of what I’m really good at, what I really care about, and what the world needs. I looked at industries that were making transformations to make the world a better place, and the more I learned about cell-based meat, the more it excited me.</p><p>Cell-based meat simultaneously solves big problems around the environment, human health, animal welfare, and food security. It’s also just really cool. It’s what we’re eating for the next century, what we’re eating in space stations, and on Mars. The more I researched it, the more I just thought it was amazing. I became involved with the Good Food Institute (GFI) and New Harvest in early 2017 and learned a lot about the space. GFI has an entrepreneur forum to meet potential co-founders. I started to look for co-founders, and that’s how I met Andra.</p><p><strong>What are you building, what’s exciting about it, what’s your company focused on, and what’s special about it?</strong></p><p>We make meat from animal cells instead of animal slaughter. We work on pork, which we chose because of the massive amount of research that’s been done on pork cell lines. There’s no animal that we consume in mass that has had more research done on it than pork.</p><p>Our big differentiator benefits from our team’s background: automation and data science. I have 12 years of industry experience automating deep research labs like NASA, US national labs, the Canadian Research Council, and the University of Texas. In those cases we put in hardware acquisition points to acquire more data and then assemble the data to make data-based decisions. Essentially that’s how you make research faster, and how you uncover connections that you didn’t know existed previously. So that’s on the deep research side. On the product side — with customers like Cisco, 3M, and GE — we ask, how do you then take that research and make products better and faster? How do you accelerate the pipeline from R&amp;D to production?</p><p>We actually started our life as a company together in November — as a horizontal company. We looked at the industry and evaluated where we could provide value. We talked to probably 150 people in existing cell-based meat companies, as well as academic researchers and nonprofit advocates. We found that people liked our vision of how to engineer biology using data science and automation, but as an incremental improvement, they didn’t see that it was pivotal to their success.</p><p>Andra’s degree from the University of Oxford is in interdisciplinary biosciences, so she took a lot of courses in engineering, statistics, math, and hardware acquisition in order to understand all the tools that she could use as a biologist to do better research.</p><p>Despite our backgrounds, when we approached companies, they just didn’t catch our vision. We were also looking at all the other companies that were providing technology and tools for human tissue engineering — like cell lines, the scaffolding, and the bioreactors. We were evaluating their capacity to re-engineer their technology to come into our market, because if they were well poised to do that, then that’s probably not a place we would provide unique value. We took a full view of the R&amp;D to product pipeline. With this understanding and with our unique differentiators, we saw that we worked best as a vertically integrated company. So in April, we decided to deliver pork to people using our technology.</p><p><strong>If you succeed, how do you think you will change the food industry landscape?</strong></p><p>We can make tastier, healthier, and more sustainable meat. The way that meat is made now is kind of a race to the bottom. There is an appetite for really cheap meat. You have industrial animal agriculture that is creating more and more negative externalities for the world: climate change, deforestation, species lost, human health concerns like antibiotic-resistant infections, concentrated animal feedlots or feed sheds, which means poor animal welfare. We can change all that.</p><p>There’s only so much you can engineer an animal to give you different tastes, textures and food experiences. With cell-based meat, we control the entire environment in which we grow our cells. This means we can start with the perception of how humans enjoy meat, and then craft our meat to deliver new, interesting, better experiences. We can also take away a lot of the negative human health aspects I mentioned before. This world of cell-based meat is obviously much better for animals. They will be able to live their own natural lives.</p><p><strong>What are the lessons learned coming from your old company to New Age Meats as CEO?</strong></p><p>My last company was a bootstrapped company, and we took no outside investment. So from the very beginning, we had customers and we grew in accordance with their demands. If we had a big customer pulling us in a certain direction, it made sense for us as a business to go in that direction. We were constantly changing in order to adapt to our big customers, because we were so driven by these short-term returns on investment. This meant that sometimes we traded a clear vision for the future of our company with short term gains. And then when those customers suddenly canceled a contract because they had cutbacks, we were stuck with a product so tailored to their use case that we couldn’t use it with other customers without extensive rework.</p><p>I have a friend outside of Silicon Valley, in Chicago. We were recently chatting and he started to poke fun at Silicon Valley companies, saying that we don’t actually care about money or return on investment. We just care about these crazy ideas.</p><p>I’ve learned so much in the past two years moving into investor backed startups. In Silicon Valley, investors want me to come in and say, “Hey, the world currently looks a certain way, but it doesn’t have to. I see the way the world <em>can</em> be, and I see a pathway for my company to come in and be the catalyst to make it that way. So, after the existing ecosystem is disrupted, we’ll be the one standing there in the new future.” They want to give me the money so that I can follow that vision and not be pulled in different directions, and in so doing, make a product that changes the world.</p><p><strong>In the short term, what are the important milestones and achievements you’re looking to hit as a company?</strong></p><p>We’re raising 3 million dollars for a seed round. We have five scientific milestones that we’re going to hit, and we have seven business and product milestones. The science milestones include making progress on the cell lines and the infrastructure with the bioreactors. Then on the business/product side, we ask, What do our customers want? What is it that we’re delivering to them? And how do we make tastes and experiences that speak to them?</p><p>That leads to product definition. What is in the product that we’re going to make? When we make our bioreactors or cultivators, what will the production facility look like? And then, what is the experience the consumers are going to be having? We’ll design all of that, so that when we go to Series A, will be able to execute on that plan.</p><p>We are leading a cultural shift. People have been increasingly eating animals from factory farms. We’re going to change that. We’re going to shift consumption to meat that’s tastier, healthier, and more sustainable. To do that, we’re having that conversation with the public early and often.</p><p><em>Watch New Age Meats pitch on </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-november-6-2018-at-herbst-theater-tickets-49655790807"><strong><em>IndieBio Demo Day</em></strong></a><em>, Tuesday Nov. 6th in San Francisco or via LiveStream. </em><a href="https://www.eventbrite.com/e/indiebio-demo-day-november-6-2018-at-herbst-theater-tickets-49655790807"><strong><em>Register here</em></strong></a><em>!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2b48dde66fc" width="1" height="1" alt=""><hr><p><a href="https://medium.com/indiebio-sf/new-age-meats-leading-a-cultural-shift-in-protein-production-2b48dde66fc">New Age Meats: Leading a Cultural Shift in Protein Production</a> was originally published in <a href="https://medium.com/indiebio-sf">IndieBio</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>